Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Sep 27 | 2022Could Novartis Deprioritize T-Charge? Novartis to Focus Exclusively on Innovative Medicines; Thoughts on Novartis Meet the Management Investor Event 2022Access Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Sep 23 | 2022Servier Discontinues Partnership with AllogeneAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Sep 23 | 2022Could JNJ Change the Treatment Paradigm in MM? Spotlight on JNJ’s MM FranchiseAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Sep 16 | 2022CHMP Adopts Positive Opinion for Yescarta; Breyanzi Absent from September’s CHMP HighlightsAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19 Sep 14 | 2022Gilead Messages on Solid Tumor Capabilities and Novel Manufacturing Methods; Gilead’s (Kite) ESMO 2022 Industry SymposiumAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19, Topics Sep 13 | 2022New Tecartus Ph2 Trial (ZUMA-25) for R/R Rare B-cell MalignanciesAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, Topics Sep 13 | 2022Updated Results from BioNTech’s BNT211; Triumvira’s TAC01-HER2 Clinical Safety and Efficacy Data; Dosing Levels of ICT’s GCC19CART; ESMO 2022 Presentations AnalysisAccess Free Blast
Free
Posted in: Autologous, TCR, Topics Sep 12 | 2022Clinical Updates from ADP-A2M4CD8’s SURPASS Study; Adaptimmune to Evaluate Multiple Combinations in the SURPASS Program; Adaptimmune’s ESMO 2022 Investor EventAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Sep 12 | 2022Type II Variations for Yescarta and Breyanzi Listed in September’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Sep 09 | 2022UPDATED: Indications Table for BCMA and CD19 CAR-Ts US Approvals and SubmissionsAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Sep 07 | 2022The EC Grants Tecartus Marketing Authorization for R/R Adult ALLAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Sep 07 | 2022New Abecma KarMMa-9 Trial for Newly Diagnosed MM PatientsAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Sep 02 | 2022Precision Appoints Cindy Atwell as CBO and Jeff Smith as CRO; Derek Jantz to Act as CEO’s PartnerAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Sep 01 | 2022Gilead / Kite Expands Cell Therapy Operations in Brazil, Singapore, and Saudi ArabiaAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Aug 30 | 2022Thoughts on Kymriah’s ≥3L r/r FL Approval in Japan; Could Kymriah’s Price Decrease? Novartis’s APAC Market Expansion StrategyAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Aug 16 | 2022Gracell’s GC012F IND Submission Plans; Ph2 Portion of GC007 Trial to Start in Q3 2022; Gracell’s Q2 2022 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Aug 16 | 2022No Cell Therapy-Related Updates in August’s CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T Aug 12 | 2022P-PSMA-101 Clinical Program Delayed; Poseida’s Global Collaboration with Roche; Poseida Q2 2022 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Aug 11 | 2022Abecma’s Ph3 KarMMa-3 Trial Meets Primary Endpoint; Potential Delays for bbT369 and SC-DARIC33; 2seventy bio Q2 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Aug 10 | 2022BMS Reports Positive Topline Results From Abecma’s Ph3 KarMMa-3 Trial for ≥3L MM vs SoC: Will Abecma be the First Approved CAR-T in ≥3L MM?Access Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.